<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cancersp</journal-id><journal-title-group><journal-title xml:lang="ru">Южно-Российский онкологический журнал/ South Russian Journal of Cancer</journal-title><trans-title-group xml:lang="en"><trans-title>South Russian Journal of Cancer</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2686-9039</issn><publisher><publisher-name>АНО "Перспективы онкологии"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37748/2686-9039-2021-2-3-5</article-id><article-id custom-type="elpub" pub-id-type="custom">cancersp-121</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Обзор</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>Значение разработки новых маннановых тестов в диагностике инвазивного кандидоза у онкологических больных</article-title><trans-title-group xml:lang="en"><trans-title>The importance of developing new mannan tests in the diagnosis of invasive candidiasis in oncology patients</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7452-6994</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куцевалова</surname><given-names>О. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutsevalova</surname><given-names>O. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Куцевалова Ольга Юрьевна – к.б.н., заведующая лабораторией клинической микробиологии, врач-бактериолог </p><p>SPIN: 6271-1942</p><p>AuthorID: 363005</p><p>ResearcherID: AAM-9837-2020 </p><p>344037, г. Ростов-на-Дону, ул. 14-я линия, д. 63</p></bio><bio xml:lang="en"><p>Olga Yu. Kutsevalova – Cand. Sci. (Biol.), head of the laboratory of clinical Microbiology, bacteriologist </p><p>SPIN: 6271-1942</p><p>AuthorID: 363005</p><p>ResearcherID: AAM-9837-2020 </p><p>63 14 line str., Rostov-on-Don 344037</p></bio><email xlink:type="simple">olga_kutsevalova@icloud.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6681-3253</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козель</surname><given-names>Ю. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozel</surname><given-names>Yu. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Козель Юлия Юрьевна – д.м.н., профессор, заведующая отделением детской онкологии </p><p>SPIN: 6923-7360</p><p>AuthorID: 732882 </p><p>344037, г. Ростов-на-Дону, ул. 14-я линия, д. 63</p></bio><bio xml:lang="en"><p>Yuliya Yu. Kozel – Dr. Sci. (Med.), professor, head of the Department of pediatric Oncology </p><p>SPIN: 6923-7360</p><p>AuthorID: 732882 </p><p>63 14 line str., Rostov-on-Don 344037</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0727-4050</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нифантьев</surname><given-names>Н. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Nifantiev</surname><given-names>N. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нифантьев Николай Эдуардович – член-корр. РАН, д.х.н., заведующий лабораторией химии гликоконъюгатов </p><p>SPIN: 5160-0379</p><p>AuthorID: 49545</p><p>ResearcherID: O-6579-2015 </p><p>119334, г. Москва, Ленинский проспект, д. 47</p></bio><bio xml:lang="en"><p>Nikolay E. Nifantiev – member of Russian Academy of Sciences, D.Sc. in Chemistry., Head of the Laboratory of Glycoconjugate Chemistry </p><p>SPIN: 5160-0379</p><p>AuthorID: 49545</p><p>ResearcherID: O-6579-2015 </p><p>47 Leninsky Prospekt, Moscow 119334</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8074-1890</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Антонец</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Antonets</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Антонец Анна Валерьевна – к.м.н., врач-генетик; научный сотрудник лаборатории химии гликоконъюгатов </p><p>SPIN: 9450-9127</p><p>AuthorID: 917704 </p><p>119334, г. Москва, Ленинский проспект, д. 47</p><p>344022, г. Ростов-на-Дону, пер. Нахичеванский, д. 29</p></bio><bio xml:lang="en"><p>Anna V. Antonets – Cand. Sci. (Med.), MD, geneticist; researcher at the Laboratory of Glycoconjugate Chemistry </p><p>SPIN: 9450-9127</p><p>AuthorID: 917704 </p><p>47 Leninsky Prospekt, Moscow 119334</p><p>29 Nakhichevansky lane, Rostov-on-don, 344022</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крылов</surname><given-names>В. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Krylov</surname><given-names>V. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Крылов Вадим Борисович – к.х.н., старший научный сотрудник лаборатории химии гликоконъюгатов </p><p>SPIN: 9750-0292</p><p>AuthorID: 153059 </p><p>119334, г. Москва, Ленинский проспект, д. 47</p></bio><bio xml:lang="en"><p>Vadim B. Krylov – PhD in Chemical sciences, senior researcher at the Laboratory of Glycoconjugate Chemistry </p><p>SPIN: 9750-0292</p><p>AuthorID: 153059 </p><p>47 Leninsky Prospekt, Moscow 119334</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ онкологии» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre for Oncology of the Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУН Институт органической химии им. Н.Д.Зелинского РАН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.D.Zelinsky Institute of Organic Chemistry of the Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУН Институт органической химии им. Н.Д.Зелинского РАН;  ФГБОУ ВО «РостГМУ» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.D.Zelinsky Institute of Organic Chemistry of the Russian Academy of Sciences; Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>06</day><month>09</month><year>2021</year></pub-date><volume>2</volume><issue>3</issue><fpage>42</fpage><lpage>47</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Куцевалова О.Ю., Козель Ю.Ю., Нифантьев Н.Э., Антонец А.В., Крылов В.Б., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Куцевалова О.Ю., Козель Ю.Ю., Нифантьев Н.Э., Антонец А.В., Крылов В.Б.</copyright-holder><copyright-holder xml:lang="en">Kutsevalova O.Y., Kozel Y.Y., Nifantiev N.E., Antonets A.V., Krylov V.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.cancersp.com/jour/article/view/121">https://www.cancersp.com/jour/article/view/121</self-uri><abstract><p>За последние годы были интенсифицированы режимы противоопухолевой терапии и внедрены методы высокодозной химиотерапии (ВДХТ), что позволило достичь значимого прогресса в результатах лечения опухолевых процессов. Интенсификация режимов химиотерапии у онкологических больных приводит к возникновению факторов рисков развития инвазивного кандидоза (ИК): агранулоцитозу, нарушению целостности слизистых оболочек, длительному применению центральных венозных катетеров (ЦВК), повторной антибактериальной терапии, длительному парентеральному питанию. Таким образом, усиление противоопухолевой терапии может сопровождаться повышением инфекционно-опосредованной летальности.Инвазивный кандидоз – самый распространенный микоз в России. Ежегодно в нашей стране возникает более 11 тысяч случаев ИК. Согласно данным многоцентровых исследований, частота ИК в России составляет 8,29 на 100 тысяч населения. В странах Европы, данный показатель варьируется от 2,2 до 11 на 100 тысяч населения. Не существует клинических признаков или симптомов, специфичных для инвазивного кандидоза который, как правило, развивается у пациентов на фоне сопутствующих заболеваний, что существенно затрудняет диагностику. В связи с этим актуальной задачей является улучшить диагностику кандидозных инфекционных осложнений у больных онкологического профиля для оптимизации лечения за счет исследования серологических маркеров, имеющих наибольшую диагностическую значимость в возникновении инфекционных осложнений у онкологических больных.</p></abstract><trans-abstract xml:lang="en"><p>The regimens of anticancer therapy have been intensified and methods of high-dose chemotherapy (HDCT) have been introduced for recent years which made it possible to achieve significant progress in the results of tumor treatments. Intensification of chemotherapy regimens in cancer patients leads to the emergence of risk factors of invasive candidiasis (IC) development: agranulocytosis, disruption of the integrity of the mucous membranes, prolonged use of CVC, repeated antibiotic therapy, long-term parenteral nutrition. Thus, intensification of anticancer therapy may be accompanied by an increase in infection-mediated mortality.IC is the most common invasive mycosis in Russia. More than 11 thousand cases of IC occur in our country every year. The frequency IC in Russia is 8.29 per 100 thousand of the population, which corresponds to the results of the LIFE study in European countries where this indicator varies from 2.2 to 11 per 100 thousand of the population. There are no clinical signs or symptoms specific for IC. It develops in patients with concomitant diseases, which significantly complicates the diagnosis. In this regard, an urgent issue is to improve the diagnosis of candidal infectious complications in cancer patients in order to optimize treatment by studying serological markers that have the greatest value in the diagnosis of infectious complications in cancer patients.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>инвазивный</kwd><kwd>кандидоз</kwd><kwd>кандидемия</kwd><kwd>онкология</kwd><kwd>Candida spp.</kwd><kwd>маннан</kwd></kwd-group><kwd-group xml:lang="en"><kwd>invasive</kwd><kwd>candidiasis</kwd><kwd>candidemia</kwd><kwd>oncology</kwd><kwd>Candida spp</kwd><kwd>mannan</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена при финансовой поддержке Российского научного фонда (грант №19-73-30017).</funding-statement><funding-statement xml:lang="en">The study was carried out with the financial support of the Russian Science Foundation (grant No. 19-73-30017).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Диникина Ю.В., Шадривова О.В., Белогурова М.Б., Игнатьева С.М., Богомолова Т.С., Климко Н.Н. Инвазивный кандидоз на фоне антифунгальной профилактики у ребенка с саркомой Юинга: описание клинического случая и обзор литературы. Онкогематология 2019;14(4):59–66. https://doi.org/10.17650/1818-8346-2019-14-4-59-66</mixed-citation><mixed-citation xml:lang="en">Dinikina YuV, Shadrivova OV, Belogurova MB, Ignatyeva SM, Bogomolova TS, Klimko NN. Breakthrough invasive candidiasis in pediatric patient with Ewing’s sarcoma: dinical case report and literature review. Oncohematology. 2019;14(4):59– 66. (In Russian). https://doi.org/10.17650/1818-8346-2019-14-4-59-66</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Михалкина Е.В., Скачкова Л.С., Кит О.И., Фоменко Ю.А. Социально-экономические предикторы злокачественных новообразований. Журнал институциональных исследований. 2020;12(3):122–141. https://doi.org/10.17835/2076-6297.2020.12.3.122-141</mixed-citation><mixed-citation xml:lang="en">Mikhalkina EV, Skachkova LS, Kit OI, Fomenko YuA. Socio-economic predictors of cancer. Journal of Institutional Research. 2020;12(3):122–141. (In Russian). https://doi.org/10.17835/2076-6297.2020.12.3.122-141</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Климко Н.Н., Козлова Я.И., Хостелиди С.Н., Шадривова О.В., Борзова Ю.В., Васильева Н.В. Распространенность тяжелых и хронических микотических заболеваний в Российской Федерации по модели LIFE Program. Проблемы медицинской микологии. 2014;16(1):3–8. Доступно по: https://mycology.szgmu.ru/files/MAPO_1_2014.pdf. Дата обращения: 16.05.2021</mixed-citation><mixed-citation xml:lang="en">Klimko NN, Kozlova YaI, Khostelidi SN, Shadrivova OV, Borzova YuV, Vasileva NV. The prevalence of serious and chronic fungal diseases in russian federation on life program model. Problems of medical mycology. 2014;16(1):3–8. Available at: https://mycology.szgmu.ru/files/MAPO_1_2014.pdf. Accessed: 16.05.2021. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2017 Oct 18;3(4):E57. https://doi.org/10.3390/jof3040057</mixed-citation><mixed-citation xml:lang="en">Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2017 Oct 18;3(4):E57. https://doi.org/10.3390/jof3040057</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012 Dec 19;4(165):165rv13. https://doi.org/10.1126/scitranslmed.3004404</mixed-citation><mixed-citation xml:lang="en">Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012 Dec 19;4(165):165rv13. https://doi.org/10.1126/scitranslmed.3004404</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Инвазивный кандидоз у новорожденных. Клинические рекомендации МЗ РФ. Москва, 2017, 34 с. Доступно по: https://dzhmao.ru/spez/klin_recom/neonatologiya/invazKandidoz.pdf. Дата обращения: 16.05.2021</mixed-citation><mixed-citation xml:lang="en">Invasive candidiasis in newborns. Clinical Guidelines of the Ministry of Health of the Russian Federation. Moscow, 2017, 34 p. Available at: https://dzhmao.ru/spez/klin_recom/neonatologiya/invazKandidoz.pdf. Accessed: 16.05.2021. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Диагностика и лечение микозов в отделениях реанимации и интенсивной терапии: Российские рекомендации. Отв. ред. Н.Н. Климко. 2-е изд. доп. и перераб. М.: Фармтек, 2015, 96 с. Доступно по: http://nasci.ru/?id=2269&amp;download=1. Дата обращения: 16.05.2021</mixed-citation><mixed-citation xml:lang="en">Diagnosis and treatment of mycoses in intensive care units: Russian recommendations. Ed. by N. N. Klimko. 2nd ed. additional and re-edited by M.: Farmtek, 2015, 96 p. Available at: http://nasci.ru/?id=2269&amp;download=1. Accessed: 16.05.2021. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004 Aug 1;39(3):309–17. https://doi.org/10.1086/421946</mixed-citation><mixed-citation xml:lang="en">Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004 Aug 1;39(3):309–17. https://doi.org/10.1086/421946</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014 Mar 27;370(13):1198–1208. https://doi.org/10.1056/NEJMoa1306801</mixed-citation><mixed-citation xml:lang="en">Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014 Mar 27;370(13):1198–1208. https://doi.org/10.1056/NEJMoa1306801</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Arastehfar A, Carvalho A, Nguyen MH, Hedayati MT, Netea MG, Perlin DS, et al. COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions? J Fungi (Basel). 2020 Oct 8;6(4):E211. https://doi.org/10.3390/jof6040211</mixed-citation><mixed-citation xml:lang="en">Arastehfar A, Carvalho A, Nguyen MH, Hedayati MT, Netea MG, Perlin DS, et al. COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions? J Fungi (Basel). 2020 Oct 8;6(4):E211. https://doi.org/10.3390/jof6040211</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015 Oct 8;373(15):1445–1456. https://doi.org/10.1056/NEJMra1315399</mixed-citation><mixed-citation xml:lang="en">Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015 Oct 8;373(15):1445–1456. https://doi.org/10.1056/NEJMra1315399</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kutsevalova O, Antonets A, Kit O, Panova N, Lysenko I, Dmitrieva V, Pak E, Kozyuk O, Marykov E, Klyasova G. New approaches to the verification of bacterial and candidal bloodstream infection. J. Fungi. 2019 Dec;5(4):208–210. https://doi.org/10.3390/jof5040095</mixed-citation><mixed-citation xml:lang="en">Kutsevalova O, Antonets A, Kit O, Panova N, Lysenko I, Dmitrieva V, Pak E, Kozyuk O, Marykov E, Klyasova G. New approaches to the verification of bacterial and candidal bloodstream infection. J. Fungi. 2019 Dec;5(4):208–210. https://doi.org/10.3390/jof5040095</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005 Sep;49(9):3640–3645. https://doi.org/10.1128/AAC.49.9.3640-3645.2005</mixed-citation><mixed-citation xml:lang="en">Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005 Sep;49(9):3640–3645. https://doi.org/10.1128/AAC.49.9.3640-3645.2005</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006 Jul 1;43(1):25–31. https://doi.org/10.1086/504810</mixed-citation><mixed-citation xml:lang="en">Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006 Jul 1;43(1):25–31. https://doi.org/10.1086/504810</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013 May;56(9):1284–1292. https://doi.org/10.1093/cid/cit006</mixed-citation><mixed-citation xml:lang="en">Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013 May;56(9):1284–1292. https://doi.org/10.1093/cid/cit006</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Колупаев В.Е., Соколинская И.Ю. Роль определения маннанового антигена и антител к маннану в диагностике инвазивного кандидоза. Ремедиум Приволжье. 2015;4(134):34–35. https://www.remedium.ru/upload/iblock/023/Remedium_4.15%20SMALL.pdf</mixed-citation><mixed-citation xml:lang="en">Kolupaev VE, Sokolinskaya IYu. The role of determining the mannan antigen and antibodies to manan in the diagnosis of invasive candidiasis. Remedium Privolzhye. 2015;4(134):34–35. https://www.remedium.ru/upload/iblock/023/Remedium_4.15%20SMALL.pdf</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C, Third European Conference on Infections in Leukemia Group. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14(6):R222. https://doi.org/10.1186/cc9365</mixed-citation><mixed-citation xml:lang="en">Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C, Third European Conference on Infections in Leukemia Group. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14(6):R222. https://doi.org/10.1186/cc9365</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008 Jun 15;46(12):1813– 1821. https://doi.org/10.1086/588660</mixed-citation><mixed-citation xml:lang="en">18. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008 Jun 15;46(12):1813–1821. https://doi.org/10.1086/588660</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">León C, Ruiz-Santana S, Saavedra P, Castro C, Loza A, Zakariya I, et al. Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Crit Care. 2016 May 16;20(1):149. https://doi.org/10.1186/s13054-016-1324-3</mixed-citation><mixed-citation xml:lang="en">León C, Ruiz-Santana S, Saavedra P, Castro C, Loza A, Zakariya I, et al. Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Crit Care. 2016 May 16;20(1):149. https://doi.org/10.1186/s13054-016-1324-3</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Verduyn Lunel FM, Donnelly JP, van der Lee H. L, Blijlevens NMA, Verweij PE. Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clin Microbiol Infect. 2009 Apr;15(4):380–386. https://doi.org/10.1111/j.1469-0691.2008.02654.x</mixed-citation><mixed-citation xml:lang="en">Verduyn Lunel FM, Donnelly JP, van der Lee H. L, Blijlevens NMA, Verweij PE. Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clin Microbiol Infect. 2009 Apr;15 (4):380–386. https://doi.org/10.1111/j.1469-0691.2008.02654.x</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Duettmann W, Koidl C, Krause R, Lackner G, Woelfler A, Hoenigl M. Specificity of mannan antigen and anti-mannan antibody screening in patients with haematological malignancies at risk for fungal infection. Mycoses. 2016 Jun;59(6):374–378. https://doi.org/10.1111/myc.12482</mixed-citation><mixed-citation xml:lang="en">Duettmann W, Koidl C, Krause R, Lackner G, Woelfler A, Hoenigl M. Specificity of mannan antigen and anti-mannan antibody screening in patients with haematological malignancies at risk for fungal infection. Mycoses. 2016 Jun;59(6):374–378. https://doi.org/10.1111/myc.12482</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62 (4):e1-50. https://doi.org/10.1093/cid/civ933</mixed-citation><mixed-citation xml:lang="en">Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15; 62 (4): e1-50. https://doi.org/10.1093/cid/civ933</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Чарушина И.П., Фельдблюм И.В., Воробьева Н.Н., Баландина С.Ю., Кузнецова М.В., Варецкая Т.А. Инвазивный кандидоз у ВИЧ-инфицированных пациентов. Федеральные клинические рекомендации. М., 2017, 46 с. http://nasci.ru/?id=2883</mixed-citation><mixed-citation xml:lang="en">Charushina IP, Feldblum IV, Vorobyeva NN, Balandina SYu, Kuznetsova MV, Verbitskaya TA. Invasive candidiasis in HIV-infected patients. Federal clinical recommendations. Moscow, 2017, 46 p. http://nasci.ru/?id=2883</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Носкова О.А., Агапова Е.Д., Батурина Е.А., Гвак Г.В. Микробиологический мониторинг в системе эпидемиологического надзора за гнойно-септическими инфекциями в детском многопрофильном стационаре. Acta Biomedica Scientifica. 2019;4(5):122–126. https://doi.org/10.29413/ABS.2019-4.5.19</mixed-citation><mixed-citation xml:lang="en">Noskova OA, Agapova ED, Baturina EA, Gvak GV. Microbiological Monitoring in the System of Epidemiological Surveillance of Purulent-Septic Infections in a Multidisciplinary Hospital. Acta Biomedica Scientifica. 2019;4(5):122–126. (In Russian). https://doi.org/10.29413/ABS.2019-4.5.19</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Гусаров В.Г., Лашенкова Н.Н., Петрова Н.В., Дементиенко М.В., Шилкин Д.Н., Нестерова Е.Е. и др. Протоколы эмпирической антимикробной терапии как инструмент улучшения качества неотложной медицинской помощи пациентам с инфекцией в многопрофильном хирургическом стационаре. Медицинский алфавит. 2016;4(33(296)):24–28.</mixed-citation><mixed-citation xml:lang="en">Gusarov VG, Lashenkova NN, Petrova NV, Dementienko MV, Shilkin DN, Nesterova EE, et al. Protocols of empirical antimicrobial therapy in improving quality of emergency medical care to patients with infection in multidisciplinary surgical hospital. Medical Alphabet. 2016;4(33(296)):24–28.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
